Hi Paperclip, valuation in 3 years will not be based on revenue of $30 - $50 M.
That Revenue estimate is for a single indication (MCT) in one species (dogs) only. Analysts will use that as a basis for estimating and modelling potential future earnings for all of the indications in all of the different species for which the drug is designed. Each of those indications will be supported by more trial data. Human data should also start to be better known by then.
Also wound healing data will be better known by then.
I think/hope your valuation (while impressive) is understating it.
Cheers
SC
- Forums
- ASX - General
- cure for cancer...you can invest
Hi Paperclip, valuation in 3 years will not be based on revenue...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
Previous Video
Next Video
SPONSORED BY The Market Online